Company PerformanceGoodRx's consistent offering of the lowest prices, achieving the lowest price 83% of the time in a benchmark study, demonstrates its competitive edge in the discount platform market.
Revenue GrowthRecent survey data suggests ISP could be significant with up to $355M in revenue, indicating a strong potential increase compared to the current estimate.
Stock ValuationAnalyst maintains a price target of $12, based on DCF analysis, implying the shares have significant upside potential with an attractive valuation multiple.